Reata Pharmaceuticals Partners Again with Abbott for US$400 M Upfront

By Heather Cartwright

Pharma Deals Review: Vol 2012 Issue 1 (Table of Contents)

Published: 6 Jan-2012

DOI: 10.3833/pdr.v2012.i1.1647     ISSN: 1756-7874

Section: Research & Development



Abbott has agreed to pay Reata Pharmaceuticals US$400 M upfront in order to gain a global licence to co-develop and co-commercialise the biotech’s preclinical, second-generation antioxidant inflammation modulators (AIM)...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details